Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1984 Sep;26(3):410–413. doi: 10.1128/aac.26.3.410

Comparison of the activities of penicillin G and new beta-lactam antibiotics against clinical isolates of Bacteroides species.

K E Aldridge, C V Sanders, A Janney, S Faro, R L Marier
PMCID: PMC176181  PMID: 6334491

Abstract

MICs were determined for 218 clinical isolates of Bacteroides by a broth microdilution method. Imipenem was the most active antibiotic tested. Azlocillin, mezlocillin, and cefoxitin had comparable activities, with resistance among members of the B. fragilis group and B. capillosus. Ceftizoxime was the most active cephalosporin tested. Members of the B. fragilis group showed high levels of resistance to cefotetan and ceftazidime. Resistance to penicillin G varied from 0 to 14%.

Full text

PDF
410

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aldridge K. E., Sanders C. V., Lewis A. C., Marier R. L. Susceptibility of anaerobic bacteria to beta-lactam antibiotics and beta-lactamase production. J Med Microbiol. 1983 Feb;16(1):75–82. doi: 10.1099/00222615-16-1-75. [DOI] [PubMed] [Google Scholar]
  2. Appelbaum P. C., Chatterton S. A. Susceptibility of anaerobic bacteria to ten antimicrobial agents. Antimicrob Agents Chemother. 1978 Sep;14(3):371–376. doi: 10.1128/aac.14.3.371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bach V. T., Thadepalli H. Susceptibility of anaerobic bacteria in vitro to 23 antimicrobial agents. Chemotherapy. 1980;26(5):344–353. doi: 10.1159/000237926. [DOI] [PubMed] [Google Scholar]
  4. Barry A. L., Jones R. N., Thornsberry C., Fuchs P. C., Gerlach E. H., Sommers H. M. Ceftizoxime: collaborative multiphased in-vitro evaluation including tentative interpretive standards for disc susceptibility tests, beta-lactamase stability, and inhibition. J Antimicrob Chemother. 1982 Nov;10 (Suppl 100):25–44. doi: 10.1093/jac/10.suppl_c.25. [DOI] [PubMed] [Google Scholar]
  5. Chow A. W., Malkasian K. L., Marshall J. R., Guze L. B. The bacteriology of acute pelvic inflammatory disease. Am J Obstet Gynecol. 1975 Aug 1;122(7):876–879. doi: 10.1016/0002-9378(75)90731-0. [DOI] [PubMed] [Google Scholar]
  6. Cuchural G., Jacobus N., Gorbach S. L., Tally F. P. A survey of Bacteroides susceptibility in the United States. J Antimicrob Chemother. 1981 Dec;8 (Suppl 500):27–31. doi: 10.1093/jac/8.suppl_d.27. [DOI] [PubMed] [Google Scholar]
  7. Darland G., Birnbaum J. Cefoxitin resistance to beta-lactamase: a major factor for susceptibility of bacteroides fragilis to the antibiotic. Antimicrob Agents Chemother. 1977 Apr;11(4):725–734. doi: 10.1128/aac.11.4.725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gall S. A., Hill G. B. High-dose cefamandole therapy in obstetric and gynecologic infections. Am J Obstet Gynecol. 1980 Aug 15;137(8):914–922. doi: 10.1016/s0002-9378(16)32832-0. [DOI] [PubMed] [Google Scholar]
  9. Kirby B. D., George W. L., Sutter V. L., Citron D. M., Finegold S. M. Gram-negative anaerobic bacilli: their role in infection and patterns of susceptibility to antimicrobial agents. I. Little-known Bacteroides species. Rev Infect Dis. 1980 Nov-Dec;2(6):914–951. doi: 10.1093/clinids/2.6.914. [DOI] [PubMed] [Google Scholar]
  10. Lee D. T., Rosenblatt J. E. A comparison of four methods for detecting beta-lactamase in anaerobic bacteria. Diagn Microbiol Infect Dis. 1983 Jun;1(2):173–175. doi: 10.1016/0732-8893(83)90048-2. [DOI] [PubMed] [Google Scholar]
  11. Malamy M. H., Tally F. P. Mechanisms of drug-resistance transfer in Bacteroides fragilis. J Antimicrob Chemother. 1981 Dec;8 (Suppl 500):59–75. doi: 10.1093/jac/8.suppl_d.59. [DOI] [PubMed] [Google Scholar]
  12. Martin D. A., Sanders C. V., Marier R. L. N-formimidoyl thienamycin (MK0787): in vitro activity against anaerobic bacteria. Antimicrob Agents Chemother. 1982 Jan;21(1):168–169. doi: 10.1128/aac.21.1.168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Neu H. C. Factors that affect the in-vitro activity of cephalosporin antibiotics. J Antimicrob Chemother. 1982 Nov;10 (Suppl 100):11–23. doi: 10.1093/jac/10.suppl_c.11. [DOI] [PubMed] [Google Scholar]
  14. Owens W. E., Finegold S. M. Comparative in vitro susceptibilities of anaerobic bacteria to cefmenoxime, cefotetan, and N-formimidoyl thienamycin. Antimicrob Agents Chemother. 1983 Apr;23(4):626–629. doi: 10.1128/aac.23.4.626. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. RIchmond M. H. The semi-synthetic thienamycin derivative MK0787 and its properties with respect to a range of beta-lactamases from clinically relevant bacterial species. J Antimicrob Chemother. 1981 Mar;7(3):279–285. doi: 10.1093/jac/7.3.279. [DOI] [PubMed] [Google Scholar]
  16. Snydman D. R., Tally F. P., Knuppel R., Landrigan J., Gorbach S. L., Bartlett J. G. Bacteroides bivius and Bacteroides disiens in obstetrical patients: clinical findings and antimicrobial susceptibilities. J Antimicrob Chemother. 1980 Jul;6(4):519–525. doi: 10.1093/jac/6.4.519. [DOI] [PubMed] [Google Scholar]
  17. Staneck J. L., Washington J. A., 2nd Antimicrobial susceptibilities of anaerobic bacteria: recent clinical isolates. Antimicrob Agents Chemother. 1974 Sep;6(3):311–315. doi: 10.1128/aac.6.3.311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Swabb E. A., Leitz M. A., Pilkiewicz F. G., Sugerman A. A. Pharmacokinetics of the monobactam SQ 26,776 after single intravenous doses in healthy subjects. J Antimicrob Chemother. 1981 Dec;8 (Suppl E):131–140. doi: 10.1093/jac/8.suppl_e.131. [DOI] [PubMed] [Google Scholar]
  19. Sweet R. L., Draper D. L., Schachter J., James J., Hadley W. K., Brooks G. F. Microbiology and pathogenesis of acute salpingitis as determined by laparoscopy: what is the appropriate site to sample? Am J Obstet Gynecol. 1980 Dec 1;138(7 Pt 2):985–989. doi: 10.1016/0002-9378(80)91093-5. [DOI] [PubMed] [Google Scholar]
  20. Tally F. P., Cuchural G. J., Jacobus N. V., Gorbach S. L., Aldridge K. E., Cleary T. J., Finegold S. M., Hill G. B., Iannini P. B., McCloskey R. V. Susceptibility of the Bacteroides fragilis group in the United States in 1981. Antimicrob Agents Chemother. 1983 Apr;23(4):536–540. doi: 10.1128/aac.23.4.536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Thadepalli H., Rao B., Dhawan V. K., Bach V. T. Evaluation of mezlocillin in aerobic and anaerobic infections. J Antimicrob Chemother. 1982 Jan;9 (Suppl A):115–119. doi: 10.1093/jac/9.suppl_a.115. [DOI] [PubMed] [Google Scholar]
  22. Weinrich A. E., Del bene V. E. Beta-lactamase activity in anaerobic bacteria. Antimicrob Agents Chemother. 1976 Jul;10(1):106–111. doi: 10.1128/aac.10.1.106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Zabransky R. J., Johnston J. A., Hauser K. J. Bacteriostatic and bactericidal activities of various antibiotics against Bacteroides fragilis. Antimicrob Agents Chemother. 1973 Feb;3(2):152–156. doi: 10.1128/aac.3.2.152. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES